Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment.

(UroToday.com) The 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting held in New Orleans, LA, was host to a Radiopharmaceutical Therapy Trials with Dosimetry session. Dr.

ASCO 2025 circulating and tumor microenvironment determinants of patient response in the Checkmate 9ER trial, nivolumab and cabozantinib in advanced renal cell carcinoma (RCC).

In part four, Alan Wein concludes his discussion with Craig Comiter about male incontinence treatment preferences. Dr. Comiter's approach is severity-based: transobturator AdVance sling for mild ...

SNMMI 2025, post-177Lu therapy, WB SPECT/CT, WB SPECT/CT Studies Post Lu 177 Therapy, 177Lu-PSMA SPECT, StarGuide scanner, 177Lu-PSMA-617 radiopharmaceutical therapy.

This study aims to evaluate the long-term outcomes of the novel "three horseshoe-like incision" (3-HSI) technique for holmium laser enucleation of the prostate (HoLEP) compared to the traditional ...

(UroToday.com) The Bladder Cancer Advocacy Network (BCAN) Bladder Cancer Think Tank 2025, held in Washington D.C., United States, was host to the session: BCAN 2023 Bladder Cancer Research Innovation ...

Dr. Lerner opened his presentation by discussing the SWOG S1011 trial, a randomized clinical study evaluating the benefit of limited versus extended pelvic lymph node dissection at the time of radical ...

Dr. Jonathan Rosenberg discussed the CALGB 90601 study and titled his talk: From lemons to lemonade, possibilities from negative cooperative group trials. Dr. Rosenberg began by highlighting one of ...

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.

Alan Bryce interviews Tanya Dorff about recommendations from the 2024 US Prostate Cancer Consensus Conference addressing clinical gray areas in prostate cancer management.

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.